2022 World Conference on Lung Cancer (ePosters)-EP02.01-011. Immune-related Histologic Phenotype in Pretreatment Tumor Biopsy Predicts Efficacy of Neoadjuvant Anti-PD-1 Treatment in Squamous Lung Cancer

EP02.01-011. Immune-related Histologic Phenotype in Pretreatment Tumor Biopsy Predicts Efficacy of Neoadjuvant Anti-PD-1 Treatment in Squamous Lung Cancer

Back to course

Pdf Summary

A study conducted by the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing aimed to develop a histologic scoring system to predict the efficacy of neoadjuvant immunotherapy in squamous lung cancer patients. They evaluated 140 non-small cell lung cancer cases, initially using surgical specimens from 31 squamous cell lung cancer patients who received neoadjuvant anti-PD-1 therapy. The pathologic evaluation of pretreatment biopsies after neoadjuvant immunotherapy was used to develop the scoring system, known as immune-related histologic phenotype assessment criteria (irHPC). The irHPC scoring system included features such as tumor infiltrating lymphocytes (TILs), eosinophils, neutrophils, macrophages, and various histological characteristics. <br /><br />The study found that patients who achieved a major pathologic response (MPR) had superior 2-year disease-free survival (DFS) rates compared to those who did not achieve MPR. The inclusion of necrosis in the calculation of the percent of residual viable tumor (%RVT) did not significantly affect the consistency of the pathologic assessment. The inter-pathologist variability for assessing %RVT with an immune-activated phenotype was not statistically significant. <br /><br />The irHPC scoring system accurately predicted the pathologic response in most cases, and patients with higher scores tended to have better 2-year DFS rates. However, larger trials are needed to further verify the predictive capability of the scoring system. Additionally, the study explored the relationship between eosinophils and PD-L1 expression in lung squamous cell carcinoma biopsies.<br /><br />In conclusion, the study suggests that the irHPC scoring system, which assesses the preexisting immune response, can be used to predict the pathologic response to neoadjuvant immunotherapy in squamous lung cancer patients. This information may help predict long-term prognosis, but further validation is needed.

Asset Subtitle

Pei Yuan

Meta Tag

Speaker Pei Yuan

Topic Early Stage Non-small Cell Lung Cancer - Biomarkers

Keywords

Cancer Hospital Chinese Academy of Medical Sciences

Peking Union Medical College

histologic scoring system

neoadjuvant immunotherapy

squamous lung cancer

non-small cell lung cancer

immune-related histologic phenotype assessment criteria

tumor infiltrating lymphocytes

eosinophils

pathologic response